Jump to:
Zach Kramer joined Ropes & Gray in 2021 as an associate in the corporate department. He practices primarily in the life sciences and intellectual property transaction groups for a range of private and public clients, with a focus on licensing agreements. During law school, Zach was a notes editor on the Public Contract Law Journal. Additionally, he worked with an advocacy group to promote tort reform across the United States of America. Upon graduation, Zach was made a member of the Order of the Coif to honor his accomplishment of graduating in the top ten percent of his Juris Doctor class. Prior to attending law school, Zach was a personal trainer and volunteered at a youth center.
Experience
- Represented Sanofi in acquisition of Dren Bio’s bispecific antibody-based program in immunology deal worth up to $1.9 billion.
- Represented Eli Lilly and Company in its $2.5 billion acquisition of Scorpion Therapeutics, a clinical-stage and precision oncology company developing cancer therapies including its oral therapy, STX-478.
- Represented a research institute in an exclusive license agreement with a biotechnology research company for certain patent rights related to self-assembling virus-like particles.
- Represented Teva Pharmaceutical Industries in a license, development and commercialization agreement with Samsung Bioepis for rare disease therapy EPYSQLI, the biosimilar to Solirisi in the U.S.
- Represented Neomorph Inc. in a research collaboration with Biogen to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases.
- Represented a global biopharmaceutical company in a collaboration and option-to-license agreement with a pharmaceutical company to develop a next generation, fully biodegradable, implant to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Represented a research institute in an exclusive license agreement with a biotechnology research company for certain patent rights related to ploy-tailed and poly-capped RNAs and uses thereof and modified mRNA and modified non-coding RNA and uses thereof.
- Represented an academic medical center in the spinout of its therapeutic research division into a wholly-owned biotech company.
- Represented Chiesi Group in a global strategic collaboration with Gossamer Bio to develop and commercialize Gossamer's pulmonary arterial hypertension treatment seralutinib.
- Represented Xcelerate Solutions, a portfolio company of McNally Capital, in its merger with VMD Corp.
- Represented Allorion Therapeutics in a global licensing agreement with Avenzo Therapeutics to develop and commercialize Allorian's AVZO-021, a cyclin-dependent kinase 2 selective inhibitor globally, excluding Greater China.
- Represented a global biopharmaceutical company in its acquisition of a medical device company focused on eliminating the left atrial appendage in patients with non-valvular atrial fibrillation to reduce the risk of stroke.
- Represented LianBio in an agreement with Bristol Myers Squibb where BMS has obtained LianBio's exclusive rights to develop and commercialize heart drug mavacamten, in mainland China, Hong Kong, Macau, Taiwan, Singapore and Thailand, in conjunction with termination of the exclusive license agreement LianBio previously entered into with MyoKardia, Inc., now a wholly owned subsidiary of BMS, in August 2020 to acquire these rights.
- Represented a global biopharmaceutical company in a collaboration agreement with a biotechnology company for to discover and develop mRNA biology modulators for multiple targets against oncology and immunology diseases.
- Represented a global biopharmaceutical company in its research and collaboration agreement with a biotechnology company for the treatment of oncological and other diseases.
- Represented a global biopharmaceutical company in a collaboration agreement with a biotechnology company for to discover and develop mRNA biology modulators for three targets against oncology and immunology diseases.
- Represented Pfizer in its $6.7 billion acquisition of Arena Pharmaceuticals, a biotechnology company developing potential therapies for the treatment of several immuno-inflammatory diseases.
- Represented Ginkgo Bioworks in an agreement to acquire biotechnology company Zymergen in an all-stock transaction that values Zymergen at approximately $300 million.
- Represented HP Inc. in acquisition of Poly Inc. in an all-cash transaction for an implied total enterprise value of $3.3 billion.
- Represented a global biopharmaceutical company in a collaboration and option agreement with a biotechnology company to discover, develop, and commercialize innovative small molecule drugs against certain oncology and immunology targets.
- Represented a biotechnology company in obtaining a license to a CRISPR nuclease to discover, develop, and commercialize certain products.
- Represented a clothing manufacture company in the purchase of certain intellectual property & other assets from various legal persons.
- Represented Kohlberg & Company portfolio company MarketCast in its add-on acquisition of Research Horizons (d/b/a Phoenix Marketing International), a provider of global marketing research and consulting services.
- Represented a pharmaceutical company in obtaining an exclusive license to a patient tracking platform from a software company.
- Represented a U.S.-based software technology company in procuring software to be jointly developed by Asia-based software development entities.
- Represented TPG Capital in its approximately $2 billion sale of Immucor, a manufacturer of transfusion and transplantation diagnostic products, to Werfen, a provider of healthcare diagnostic services based in Spain.